|Articles|November 18, 2003
FDA approves CrystaLens, first accommodating IOL
Eyeonics inc. (formerly C&C Vision) received FDA approval to marketthe CrystaLens, the first accommodating IOL that allows patients to focusautomatically and seamlessly at all distances.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO
2
Precise Bio completes procedure using PB-001, a 3D-bioprinted corneal implant
3
Corza Medical announces launch of the SensorTek ROP Kit
4
Defining Retinal Vascular Diseases AMD, DME, RVO
5














































.png)


